NeuBase Therapeutics, Inc.

NasdaqCM:NBSE Stock Report

Market Cap: US$1.4m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

NeuBase Therapeutics Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Todd Branning

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure2.3yrs
CEO ownership0.04%
Management average tenureno data
Board average tenure3.5yrs

Recent management updates

Recent updates

Analysis Article • Aug 26

Can NeuBase Therapeutics (NASDAQ:NBSE) Afford To Invest In Growth?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Seeking Alpha • Aug 11

NeuBase Therapeutics GAAP EPS of -$0.26 beats by $0.04

NeuBase Therapeutics press release (NASDAQ:NBSE): Q3 GAAP EPS of -$0.26 beats by $0.04. As of June 30, 2022, the Company had cash and cash equivalents of approximately $29.8 million, compared with approximately $52.9 million as of September 30, 2021.
Seeking Alpha • Jun 29

NeuBase Therapeutics promotes Dr. William Mann to President and COO

NeuBase Therapeutics (NASDAQ:NBSE) promotes William (Bill) Mann, Ph.D. to President of the company, effective immediately.  Dr. Mann will also continue to serve as the company’s COO. Dr. Mann joined the company as CCO in July 2020. Prior to joining the company, Dr. Mann served as the President, CEO, and board member of Helsinn Therapeutics U.S.
Analysis Article • May 12

We Think NeuBase Therapeutics (NASDAQ:NBSE) Needs To Drive Business Growth Carefully

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Analysis Article • Jan 24

Is NeuBase Therapeutics (NASDAQ:NBSE) In A Good Position To Deliver On Growth Plans?

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Analysis Article • Oct 02

Here's Why We're Not Too Worried About NeuBase Therapeutics' (NASDAQ:NBSE) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Analysis Article • Jun 02

Here's Why We're Not Too Worried About NeuBase Therapeutics' (NASDAQ:NBSE) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Feb 23

Have Insiders Been Buying NeuBase Therapeutics, Inc. (NASDAQ:NBSE) Shares This Year?

We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly...
Analysis Article • Jan 19

We Think NeuBase Therapeutics (NASDAQ:NBSE) Can Afford To Drive Business Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Analysis Article • Dec 15

Do Insiders Own Lots Of Shares In NeuBase Therapeutics, Inc. (NASDAQ:NBSE)?

The big shareholder groups in NeuBase Therapeutics, Inc. ( NASDAQ:NBSE ) have power over the company. Institutions will...

CEO Compensation Analysis

How has Todd Branning's remuneration changed compared to NeuBase Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2023n/an/a

-US$25m

Dec 31 2022n/an/a

-US$30m

Sep 30 2022US$922kUS$311k

-US$34m

Compensation vs Market: Insufficient data to establish whether Todd's total compensation is reasonable compared to companies of similar size in the US market.

Compensation vs Earnings: Insufficient data to compare Todd's compensation with company performance.

CEO

Todd Branning (53 yo)

2.3yrs
Tenure
US$922,445
Compensation

Mr. Todd P. Branning serves as an Interim Chief Executive Officer since January 16, 2024 and Chief Financial Officer of NeuBase Therapeutics, Inc. since January 2022 and serves as its Secretary. He joined...

Board Members

NamePositionTenureCompensationOwnership
Dietrich Stephan
Founder4.8yrsUS$1.15m6.14%
$ 87.1k
Dov Goldstein
Independent Chairperson4.8yrsUS$74.42k0.040%
$ 567.0
Eric Richman
Independent Director4.8yrsUS$68.38k0.060%
$ 849.3
George Church
Chairperson of Gene Editing Advisory Board & Member of Scientific Advisory Board1yrno datano data
Steven Dowdy
Member of Gene Editing & Scientific Advisory Board4.6yrsno datano data
James Coull
Member of Gene Editing Advisory Board1yrno datano data
Randy Davis
Member of Scientific Advisory Board3.5yrsno datano data
Danith Ly
Member of Advisory Boardno datano datano data
Robert Friedlander
Chair of Scientific Advisory Boardno datano datano data
Peter Nielsen
Member of Gene Editing & Scientific Advisory Board3.6yrsno datano data
Eriks Rozners
Member of Gene Editing & Scientific Advisory Board3.5yrsno datano data
Gerald Mcdougall
Independent Director3yrsUS$59.79k0%
$ 0
3.5yrs
Average Tenure
56yo
Average Age

Experienced Board: NBSE's board of directors are considered experienced (3.5 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/05/13 11:01
End of Day Share Price 2024/05/13 00:00
Earnings2023/03/31
Annual Earnings2022/09/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

NeuBase Therapeutics, Inc. is covered by 6 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Thomas ShraderBTIG
Whitney IjemGuggenheim Securities, LLC
Raghuram SelvarajuH.C. Wainwright & Co.